Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway

Wu, Liwei; Liang, Jiamin; Li, Jing; Xu, Yang; Chen, Junchun; Su, Yuangang; Xian, Yansi; Wei, Jiyong; Xu, Jiake; Zhao, Jinmin; Liu, Qian; Yang, Yuan

doi:10.1016/j.ejphar.2022.174908

Cited by 5 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we found that cilengitide principally affected the late stage of osteoclast formation. Considering that obtaining a higher number of BMM cells, these cells were collected from the femur and tibia [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway

Guo

Chen

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…The femur and tibia of C57BL/6 mice (age:7±1weeks, weight:22 ± 2 g, purchased from Kawensi, Changzhou, China) were utilized to harvest total bone marrow cells [ 22 ]. These cells were subsequently cultured in culture medium supplemented with 10% FBS, 1% penicillin and streptomycin, and 30 ng/ml M-CSF at 37 °C and 5% CO 2 [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway

Guo

Chen

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Nevertheless, regenerating damaged bone tissue in osteoporosis patients remains a therapeutic challenge. Conventional antiosteoporotic medications can improve conditions to some degree but cannot effectively repair affected areas, with long-term use incurring more side effects (Li J. et al, 2022;Chen et al, 2022;Long et al, 2022;Wu et al, 2022). Therefore, searching for a safe and efficacious osteoporosis drug is imperative.…”

Section: Introductionmentioning

confidence: 99%

Unveiling the potential of Butylphthalide: inhibiting osteoclastogenesis and preventing bone loss

Yanbin,

Yilin,

Yaomin

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Osteoporosis, resulting from overactive osteoclasts and leading to elevated fracture risk, has emerged as a global public health concern due to the aging population. Therefore, inhibiting osteoclastogenesis and bone resorption function represents a crucial approach for preventing and treating osteoporosis. The purpose of this study was to examine the effects and molecular mechanisms of Butylphthalide (NBP) on the differentiation and function of osteoclasts induced by RANKL. Osteoclastogenesis was assessed through TRAP staining and bone slice assay. An animal model that underwent ovariectomy, simulating postmenopausal women’s physiological characteristics, was established to investigate the impact of Butylphthalide on ovariectomy-induced bone loss. To delve deeper into the specific mechanisms, we employed Western blot, PCR, immunofluorescence, and immunohistochemical staining to detect the expression of proteins that are associated with the osteoclast signaling pathway. In this study, we found that Butylphthalide not only suppressed osteoclastogenesis and bone resorption in vitro but also significantly decreased TRAcP-positive osteoclasts and prevented bone loss in vivo. Further mechanistic experiments revealed that Butylphthalide reduces intracellular ROS in osteoclasts, inhibits the MAPK and NFATc1 signaling pathways, and downregulates the key genes and proteins of osteoclasts. This inhibits osteoclast formation and function. The reduction in ROS in osteoclasts is intricately linked to the activity of Butylphthalide-modulated antioxidant enzymes. Overall, NBP may offer a alternative treatment option with fewer side effects for skeletal diseases such as osteoporosis.

show abstract

Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL‐induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation

Song

Lin

et al. 2023

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway

Cited by 5 publications

References 62 publications

Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway

Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway

Unveiling the potential of Butylphthalide: inhibiting osteoclastogenesis and preventing bone loss

Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL‐induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation

Contact Info

Product

Resources

About